CooperCompanies stock gets six new lens launches in view
Published on 09/29/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CooperCompanies (ISIN US21664P1039) is advancing six CooperVision contact lens programs after opening a global innovation hub on September 23, 2026. The Nasdaq-listed medical device company is pairing that pipeline with a fiscal 2026 revenue outlook of USD 4.229 billion to USD 4.252 billion.
Six launches target vision growth
According to StockTitan on September 23, 2026, CooperVision outlined six advancements at The Vision Centre in Southampton, including daily lenses for myopia control, silicone hydrogel products, and new toric and multifocal designs. CooperVision expects the products to launch over the next several years.
The innovation push addresses a visible operating gap in fiscal Q3. CooperVision revenue was USD 717.0 million for the quarter ended July 31, 2026, unchanged from the prior-year quarter, while CooperSurgical revenue increased 2.00 percent to USD 349.2 million, according to CooperCompanies in its September 9, 2026 results release.
Quarterly cash flow remains central
Consolidated fiscal Q3 revenue rose 1.00 percent year over year to USD 1.066 billion. Non-GAAP diluted EPS reached USD 1.15, up 4.00 percent, while free cash flow increased 66.00 percent to USD 273.0 million.
The earnings mix requires care. GAAP diluted EPS was USD 2.24, compared with USD 0.49 a year earlier, but the result included a USD 307.2 million discrete tax benefit tied to the favorable completion of a U.K. tax examination. The same release also reported USD 339.1 million of share repurchases during the quarter.
Guidance sets the valuation test
For fiscal 2026, CooperCompanies guided to non-GAAP diluted EPS of USD 4.51 to USD 4.55 and organic revenue growth of 2.00 percent to 3.00 percent. Fourth-quarter revenue guidance is USD 1.057 billion to USD 1.080 billion, while fourth-quarter non-GAAP EPS guidance is USD 1.05 to USD 1.09.
According to MarketBeat on September 9, 2026, the average analyst price target was USD 81.64 and the consensus rating was Hold. The report also said fourth-quarter EPS guidance was below the USD 1.20 consensus estimate, making execution in CooperVision and the new product pipeline important valuation tests.
Nasdaq value and trading range
The latest Nasdaq quote supplied for CooperCompanies was USD 56.57 on September 28, 2026 at 4:00 p.m. ET. The 52-week range was USD 51.01 to USD 89.83, and market capitalization stood at USD 11.0 billion as of September 28, 2026.
CooperCompanies key data
- Company: The Cooper Companies, Inc.
- ISIN: US21664P1039
- Ticker: COO
- Primary exchange: Nasdaq
- Market capitalization: USD 11.0 billion (as of September 28, 2026)
- 52-week range: USD 51.01-USD 89.83 (as of September 28, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
